RxDoctor Payments Data

Jiyo Shin, MD

Family Medicine · Smyrna, GANPI 1922282102

Payments from drug & device makers

$2,770in general payments, 2019–2025

Across 132 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$436
  • Pfizer$243
  • GSK$192
  • Astellas Pharma US Inc$190
  • Lilly USA, LLC$158
  • AbbVie$155
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$2,770100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,770 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$48,354
Medicare patients
166
Services billed
485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$54,520
JardianceEmpagliflozin35$49,400
MounjaroTirzepatide18$27,481
RybelsusSemaglutide19$27,086
EliquisApixaban27$24,736
MyrbetriqMirabegron20$17,379
TrulicityDulaglutide12$16,338
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,112
SymbicortBudesonide/Formoterol Fumarate12$2,798
Atorvastatin Calcium317$2,073
Rosuvastatin Calcium184$2,027
Losartan Potassium192$1,779
Ezetimibe60$1,707
Pantoprazole Sodium106$1,683
Potassium Chloride63$1,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$436$81,60551 claims
Boehringer IngelheimJardiance$137$49,40035 claims
Lilly USA, LLCMounjaro, Trulicity$158$43,81930 claims
PfizerEliquis$243$24,73627 claims
Astellas Pharma US IncMyrbetriq$190$17,37920 claims
AstraZenecaSymbicort$99$2,79812 claims
AbbVieSynthroid$155$1,53519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Smyrna

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →